C101248 / Cerevance - LARVOL DELTA

Cerevance Announces Poster Presentation at the BNA International Festival of Neuroscience (GlobeNewswire) - "Cerevance...today announced a poster presentation at the British Neuroscience Association (BNA) 2023 International Festival of Neuroscience in Brighton, United Kingdom being held April 23-26, 2023."

Clinical • Alzheimer's Disease • CNS Disorders

NETSSEQ REVEALS DEEP MOLECULAR INSIGHTS INTO ALZHEIMER'S DISEASE PROGRESSION AND FACILITATES IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS (ADPD 2023) - "Here, we describe a novel target that modulates NLRP3-inflammasome activity, as well as C101248, the first selective small molecule inhibitor of this target...Many genes are expressed specifically in microglia and change across the AD disease continuum, potentially contributing to disease progression. These data are being harnessed to identify and select novel targets for drug discovery, which will hopefully result in life changing therapeutics for AD and other diseases."

Alzheimer's Disease • CNS Disorders • NLRP3

Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology (GlobeNewswire) - “Cerevance…today announced the presentation of preclinical data supporting the use of the company’s Nuclear Enriched Sort sequencing (NETSseq) technology platform to identify novel, druggable targets involved in the regulation of neuroinflammation in Alzheimer’s disease (AD). The data will be presented during the CSHL Neurodegenerative Disease - Biology and Therapeutics Conference held at the Cold Spring Harbor Laboratory from November 30 – December 2, 2022….In addition, this data has been published in the peer-reviewed journal Neuropharmacology….C101248 demonstrated a selective and concentration-dependent inhibition of the THIK-1 protein in human and mouse cells. In mouse microglia, inhibition of THIK-1 with C101248 attenuated activity of the NLRP3 inflammasome and corresponded with a reduction of IL-1β, key components in the development of inflammation in AD.”

Preclinical • Alzheimer's Disease • CNS Disorders